Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

US: FDA educating healthcare professionals about cannabinoid market in webinars

Federal officials from the U.S. Food and Drug Administration (FDA) met this week for a wide-ranging educational webinar about cannabis, outlining matters such as the plant's chemical makeup, differences between marijuana and hemp, clinical and therapeutic effects of cannabinoids as well as ongoing health and safety concerns around the drug's use.

Hosted by FDA's Division of Drug Information, which is part of the agency's Center for Drug Evaluation and Research (CDER), the webinar was designed to provide information "targeting the needs of all health care professionals, including physicians, physician assistants, nurse practitioners, nurses, pharmacists, pharmacy technicians, and certified public health professionals."

The event comes as the federal government considers the Biden administration's proposed rescheduling of cannabis, which would move it from Schedule I to Schedule III of the federal Controlled Substances Act (CSA), effectively legalizing certain FDA-approved forms of medical marijuana.

Read more at Marijuana Moment

Publication date: